Onco-Hu® Models are a robust immuno-oncology platform for efficacy testing of novel immunotherapies targeting T cells and myeloid cells to help destroy cancers in vivo.
Humanized NSG™ and NSG™-SGM3 mouse models are powerful tools for studying cancer, inflammatory and infectious disease, and hematopoiesis. We maintain large on-the-shelf inventories of two versatile humanized models. Both are popular models for checkpoint inhibitor development.
Our collections of humanized NSG™ and NSG™-SGM3 mice generate functional human immune systems with expansive capabilities. Mouse models with humanized immune systems represent ground-breaking platforms to evaluate compounds to treat a variety of human diseases, from cancer and infectious diseases to allergies, inflammation and Graft versus Host Disease.
The hosts for hu-CD34 and hu-PBMC models are NOD scid gamma (NSG™) mouse, developed by JAX Professor Lenny Shultz and the NSG™-SGM3 strain, shown to support greater engraftment of human hematopoietic stem cells (hu-CD34+ cells) than all other strains.
Humanized CD34+ mice (hu-CD34) are a robust in vivo platform for analyzing the safety and effectiveness of potential new drugs to modulate the immune system. Hu-CD34 mice are supreme in vivo models for long-term studies in the fields of immuno-oncology, infectious disease, and graft versus host disease.
Models engrafted with cord blood-derived hematopoietic stem cells (HSC) develop a functional human immune system and display robust T-cell maturation and T-cell dependent inflammatory responses. Large cohorts of humanized CD34+ NSG™ and NSG™-SGM3 mice are available for immediate delivery or to enroll in JAX drug efficacy testing services.
Humanized PBMC (hu-PBMC) mice are used as in vivo models to study and evaluate compounds for infectious diseases and graft rejection research. Hu-PBMC models have the fastest engraftment rate using adult peripheral blood mononuclear cells and enable short-term studies requiring a strong effector and memory T cell and NK cell function.
NSG™ mice are a proven host for engraftment of human tumors or establishment of human immunity following hematopoietic stem cell transplantation. This guide explains why the interactions between human immune cells and tumors are paramount when devising treatment strategies that prevent tumor evasion of immune cells and improve cytotoxic responses.
Develops immunodeficient mouse models and optimizes technologies for effective human cell and tissue engraftment.
In this webinar, our panel of experts will discuss the successes and caveats of using humanized mouse models to understand disease biology and evaluate therapeutic strategies.
The NOD scid gamma mouse uniquely supports the engraftment of human hematopoietic cells, enabling the creation of “humanized” NSG (huNSG) mice.
Genome editing with CRISPR/Cas9 enables the generation of new mouse models with unprecedented speed and simplicity. The Jackson Laboratory was an early adopter of CRISPR/Cas9 technology for mouse model development, and in this brief guide we describe the technology and lessons learned to generate knockouts and knockins in more than a dozen different genetic backgrounds.
Here are 10 reasons to use hu-NSG™ models to test drugs that modulate the human immune system, and also as refined models for infectious diseases.
The monthly NSG™ Mice Pub Alert features recent high impact publications that utilize the NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG™) mouse.
Humanized mouse models, where human tumor tissue is engrafted into immunodeficient NOD SCID gamma (NSG) mice, are frequently used in oncology and infectious disease studies to provide valuable translational insights.
This webinar highlights recent advances and future directions using humanized NSG™ mice with functional human immune cells, to study human infectious diseases including HIV.